BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC).
The vaccine is claimed to use the same mRNA technology that proved instrumental in Covid-19 vaccines.
Go deeper with GlobalData
Unlike vaccines for viral infections, BNT116 aims to prime the immune system to recognise and attack cancer cells.
BNT116 introduces the immune system to tumour markers associated with NSCLC. This approach trains the body’s defences to detect and destroy cancer cells displaying these markers, the company noted.
The vaccine’s targeted mechanism is designed to bolster the immune response against cancer while minimising collateral damage to healthy cells, a common issue with traditional chemotherapy.
The trial will be conducted across seven countries and will involve approximately 130 patients with varying stages of lung cancer, from early to advanced or recurrent types.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataParticipants will receive BNT116 in combination with immunotherapy, a strategy that enhances the potential efficacy of the treatment.
A key benefit of BNT116 is its potential to decrease lung cancer recurrence, possibly improving long-term survival rates for patients.
As the trial progresses, researchers will evaluate the effectiveness of the vaccine in preventing lung cancer relapse.
Positive results could pave the way for mRNA cancer vaccines to become a standard treatment option globally.
In June this year, the US Food and Drug Administration placed a partial clinical hold on BioNTech’s Phase I trial of an early-stage antibody-drug conjugate (ADC) BNT326/YL202 after deaths were reported.
mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
